Decline in serum 25 hydroxyvitamin D levels in HIV-HBV-coinfected patients after long-term antiretroviral therapy

A Avihingsanon; T Apornpong; RA Ramautarsing; S Ubolyam; P Tangkijvanich; J Ananworanich; JMA Lange; G Matthews; SR Lewin; K Ruxrungtham

Journal article

Decline in serum 25 hydroxyvitamin D levels in HIV-HBV-coinfected patients after long-term antiretroviral therapy

A Avihingsanon, T Apornpong, RA Ramautarsing, S Ubolyam, P Tangkijvanich, J Ananworanich, JMA Lange, G Matthews, SR Lewin, K Ruxrungtham

Antiviral Therapy | INT MEDICAL PRESS LTD | Published : 2014

DOI: 10.3851/IMP2673

Abstract

Background: Vitamin D insufficiency plays an important role in the development of fibrosis in chronic liver disease. Methods: This was a cross-sectional study from Thailand. Liver fibrosis was assessed by transient elastography. Serum 25 hydroxyvitamin D (25[OH]D)14 kPa. Median (IQR) duration on TDF was 5 years (4-7). The median estimated glomerular filtration rate was 96.9 ml/min/1.73 m2. The median (IQR) serum 25(OH)D levels prior to and following TDF were 24.8 ng/ml (21.3-30.6) and 22.8 ng/ml (18.0-27.7), respectively; P≤0.001). The proportion of patients with hypovitaminosis D significantly increased from 72.2% (95% CI 64.7, 78.6) prior to TDF to 84.2% (95% CI 77.7, 89.0) after taking TD..

View full abstract

University of Melbourne Researchers

Sharon Lewin Author

Related Projects (2)

IMPROVED HEALTH OUTCOMES FOR PEOPLE LIVING WITH HIV

Despite the success of antiviral therapy for HIV infection, HIV cannot be cured and treatment is life long. In addition, there are complicat..

HIV-HBV CO-INFECTION

Morbidity and mortality secondary to liver disease is greatly increased in people co-infected with HIV and HBV compared to those infected wi..

Grants

Awarded by National Research Council of Thailand (NRCT)

Awarded by Thailand Research Fund (TRF)

Awarded by Ratchadapisek Sompotch Endowment Fund (Faculty of Medicine, Chulalongkorn University)

Funding Acknowledgements

This study (clinical trial number NCT01138241) was funded by the National Research Council of Thailand (NRCT) under grant number Por Kor/2554-136 (5 September 2011), the Thailand Research Fund (TRF) under grant number RSA5380002, BRG5580005, the Ratchadapisek Sompotch Endowment Fund (Faculty of Medicine, Chulalongkorn University) under grant number RA33/53 (25 June 2010), Research Unit of Hepatitis and Liver Cancer, Chulalongkorn University, and the Aligning Care and Prevention of HIV/AIDS with Government Decentralization to Achieve Coverage and Impact (ACHIEVED Project; The Global fund Project, Thailand).